<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arnold S Freedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jon C Aster, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Claire Dearden, MD, BSc, FRCP, FRCPath
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Lister, MD, FRCP, FRCPath, FRCR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rebecca F Connor, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         T cell prolymphocytic leukemia (T-PLL) is a rare, clinically aggressive T cell neoplasm composed of lymphoid cells, typically with involvement of the peripheral blood, bone marrow, lymph nodes, and spleen. The name "prolymphocyte" is a misnomer, as the tumor cells in this disease are of post-thymic T cell origin. This class of neoplasms includes many cases previously classified as T cell chronic lymphocytic leukemia, a category no longer included in the current World Health Organization classification.
        </p>
        <p>
         The epidemiology, clinical presentation, pathology, and diagnosis of T-PLL are discussed here. The treatment and prognosis of T-PLL are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/13937.html" rel="external">
          "Treatment of T cell prolymphocytic leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         T-PLL is an extremely rare disease, comprising approximately 2 percent of mature lymphocytic leukemias in adults [
         <a href="#rid1">
          1-3
         </a>
         ]. Sporadic T-PLL mainly affects older adults with a mean age at presentation of 63 to 65 years [
         <a href="#rid4">
          4,5
         </a>
         ]. It has not been definitively reported in children or young adults. There is a slight male predominance with a male:female ratio of 1.33 [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Patients with ataxia telangiectasia have a greatly increased incidence of T-PLL with a different epidemiologic profile [
         <a href="#rid6">
          6
         </a>
         ]. In contrast to patients with sporadic T-PLL, the median age of onset of T-PLL in patients with ataxia telangiectasia is about 30 years, and some cases appear in adolescence [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">
          "Ataxia-telangiectasia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         T-PLL is a clinically aggressive disease. Given its rarity, there is uncertainty regarding the frequency of various clinical and laboratory findings at diagnosis. Most patients present with an elevated white blood count (typically &gt;100,000/microL).
        </p>
        <p>
         On examination, hepatosplenomegaly (75 percent) and generalized lymphadenopathy (50 percent) are common; anemia (36 percent) and thrombocytopenia (51 percent) can be seen but are less common than in B cell prolymphocytic leukemia [
         <a href="#rid2">
          2,5
         </a>
         ]. In addition, skin infiltration and serous effusions (eg, pleural, peritoneal) occur in approximately 25 and 15 percent of patients, respectively. Peripheral, periorbital, and conjunctival edema are also seen. Involvement of the central nervous system is rare. Systemic B symptoms (unexplained fevers/chills, night sweats, weight loss) are uncommon at the time of diagnosis but can develop as the disease progresses.
        </p>
        <p>
         Approximately 15 to 20 percent of patients will be entirely asymptomatic at the time of diagnosis and have disease that remains stable or progresses slowly over years [
         <a href="#rid8">
          8,9
         </a>
         ]. This clinical presentation has been termed "inactive T-PLL." Such patients have been diagnosed at an earlier period in their disease and the disease tempo will increase over time to "active T-PLL."
        </p>
        <p>
         Testing for human T lymphotropic virus (HTLV) types 1 or 2 is negative.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATHOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Morphology
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Peripheral blood and bone marrow
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examination of the peripheral blood demonstrates a predominance of lymphoid cells  (
         <a class="graphic graphic_picture graphicRef85962 graphicRef64572" href="/z/d/graphic/85962.html" rel="external">
          picture 1A-B
         </a>
         ). There are three morphologic variants [
         <a href="#rid1">
          1,2,10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Typical (75 percent) – The tumor cells are medium-sized lymphoid cells with moderately condensed chromatin and a visible nucleolus. The nucleus can be round or oval. The cytoplasm is usually moderately abundant and slightly basophilic without granules. Cytoplasmic protrusions (blebs) are common.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small cell variant (20 percent) – The tumor cells are small with condensed chromatin and a small nucleolus visible only by electron microscopy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebriform (Sézary cell-like) variant (5 percent) – The tumor cells have a very irregular nuclear outline resembling the cerebriform nucleus of Sézary cells seen in Sézary syndrome.
        </p>
        <p>
        </p>
        <p>
         The bone marrow is infiltrated in an interstitial pattern by cells with similar morphology.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Skin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin infiltrations most commonly involve the trunk or the limbs and produce an erythematous maculopapular rash; nodular skin involvement may also be seen. T-PLL may also involve the face, where it manifests as purpura and edema, often in a periorbital distribution  (
         <a class="graphic graphic_picture graphicRef85961" href="/z/d/graphic/85961.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid11">
          11,12
         </a>
         ]. Skin biopsy of affected areas demonstrates perivascular or diffuse dermal infiltrates, sometimes with accompanying hemorrhage, but without epidermotropism.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Other tissues
         </span>
         <span class="headingEndMark">
          —
         </span>
         The spleen demonstrates dense lymphoid infiltrates in the red pulp that often invade the splenic capsule. The white pulp is usually atrophied. Lymph node involvement is diffuse, often with prominent high-endothelial venules. Infiltration typically involves the paracortical areas and may spare the follicles.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Immunophenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         T-PLL cells express CD52 (strongly) and pan-T cell markers (CD2, CD3, and CD7)  (
         <a class="graphic graphic_figure graphicRef85963" href="/z/d/graphic/85963.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Terminal deoxynucleotidyl transferase (TdT) is not expressed. CD3 may be expressed on the cell membrane at low or high levels. Expression of CD4 and CD8 is variable: 60 percent of cases are CD4+/CD8-, 25 percent of cases are CD4+/CD8+, and 15 percent of cases are CD4-/CD8+. The coexpression of CD4 and CD8 is practically unique to T-PLL among post-thymic T cell malignancies. T-PLL cells overexpress the oncogene TCL1 as demonstrated by immunohistochemistry and by flow cytometry.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Genetic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         T cell receptor genes are clonally rearranged. Chromosomal abnormalities are common, and 70 to 80 percent of cases have complex karyotypes [
         <a href="#rid13">
          13
         </a>
         ]. One of the following rearrangements involving a member of the T cell leukemia/lymphoma 1 family of genes (TCL1A, TCL1B, or MTCP1) is seen in over 90 percent of cases, and each is relatively specific for T-PLL [
         <a href="#rid1">
          1,6,13-16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         inv(14)(q11q32)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         t(14;14)(q11;q32)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         t(X;14)(q28;q11)
        </p>
        <p>
        </p>
        <p>
         These rearrangements involve either TCL1 at 14q32.13 or MTCP1 (a homolog of TCL1) at Xq28. They lead to aberrant expression of the TCL1 or MTCP1 proteins, which can be detected by immunohistochemistry or flow cytometry (at some centers). Fluorescence in situ hybridization (FISH) and immunohistochemistry (to detect aberrant protein expression) are more sensitive than cytogenetics for the detection of these abnormalities [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Additional chromosomal or genetic abnormalities, which are not specific to T-PLL but help to support the diagnosis include [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities in chromosome 8 (70 to 80 percent of cases) including isodicentric 8p11, t(8;8), and trisomy 8q [
         <a href="#rid15">
          15,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Deletions or missense mutations involving the ataxia telangiectasia mutated (ATM) locus 11q23 (65 percent) [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities in chromosomes 5, 12, 13, or 22; or a complex karyotype [
         <a href="#rid13">
          13,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Haploinsufficiency for the CDKN1B tumor suppressor gene at 12p13 is found in approximately 50 percent of cases [
         <a href="#rid13">
          13
         </a>
         ]. Other common findings include activating mutations in the JAK1 (1p31.3) or JAK3 (19p13.11) non-receptor tyrosine kinases (34 to 38 percent), abnormalities in chromosome 6 (33 percent) and chromosome 17 (26 percent), and deletion of the TP53 gene at 17p13 (50 percent) [
         <a href="#rid6">
          6,18,21-24
         </a>
         ].
        </p>
        <p>
         A subset of cases also have been reported to have mutations in STAT5B, the small GTP-binding protein RHOA, and the epigenetic regulators EZH2, TET2, and BCOR, none of which are specific for T-PLL [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H823167492">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of T-PLL should be suspected in an adult found to have an absolute lymphocytosis, often with few additional symptoms. Evaluation of such patients should include [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A complete blood count with differential
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examination of the peripheral smear
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow cytometry and immunostains to determine the immunophenotype of the circulating lymphocytes in the peripheral blood, and to test for aberrant TCL1 and MTCP1 expression
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T cell receptor analysis of the circulating lymphocytes (with polymerase chain reaction [PCR] or next-generation sequencing)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing for human T lymphotropic virus (HTLV) type 1 (to exclude adult T cell leukemia-lymphoma)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Karyotyping
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluorescence in situ hybridization to look for rearrangements involving TCL1 and MTCP1
        </p>
        <p>
        </p>
        <p>
         Evaluation of the bone marrow is not usually necessary but is included in the evaluation of patients with unexplained cytopenias or diagnostic uncertainty. The urgency of evaluation is guided by the patient's clinical condition. Most patients are clinically stable and can be evaluated, diagnosed, and managed as outpatients. Rarely, patients will present with complications secondary to rapid disease progression and require hospitalization for stabilization and diagnostic evaluation.
        </p>
        <p class="headingAnchor" id="H548110501">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on the evaluation above, T-PLL can be diagnosed using the following major and minor criteria proposed by The T-PLL International Study Group (TPLL-ISG) [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p>
         Major criteria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cells with T-PLL phenotype in peripheral blood or bone marrow &gt;5000/microL (5 x 10
         <sup>
          9
         </sup>
         /L)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clonality of the T lymphocytes by PCR for T cell receptor rearrangement or by flow cytometry
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities of 14q32 or Xq28, or expression of TCL1 or MTCP1
        </p>
        <p>
        </p>
        <p>
         Minor criteria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities involving chromosome 11 (11q22.3; ATM)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities in chromosome 8: idic(8)(p11), t(8;8), trisomy 8q
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities in chromosome 5, 12, 13, 22, or complex karyotype
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement of T-PLL specific site (eg, splenomegaly, effusions)
        </p>
        <p>
        </p>
        <p>
         The diagnosis of T-PLL requires all three major criteria, or fulfillment of the first two major criteria plus one minor criterion. All cases of T-PLL meet the first two major criteria, and the third major criterion is present in more than 90 percent of cases. The remainder of cases can be captured using the minor criteria and are collectively referred to as "TCL1-family negative T-PLL."
        </p>
        <p>
         As described above, the typical T-PLL phenotype includes expression of CD52 and the pan-T cell markers CD2, CD3, and CD7; surface expression of CD3 is absent in about one-third of cases, but CD3 is present in the cytoplasm of the tumor cells in such cases. Expression of CD4 and CD8 vary. Serologic and PCR testing for HTLV type I is negative thereby ruling out adult T cell leukemia-lymphoma.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of T-PLL includes other chronic lymphoid neoplasms or T cell neoplasms with a leukemic presentation. The main entities are described in more detail below, and a broader differential is included in the table  (
         <a class="graphic graphic_table graphicRef56540" href="/z/d/graphic/56540.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          B cell prolymphocytic leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         B cell prolymphocytic leukemia (B-PLL) has a similar clinical presentation and morphologic appearance to T-PLL. Skin infiltration and lymphadenopathy, which are unusual in B-PLL, are much more common in T-PLL. These two entities differ in their immunophenotype. Unlike T-PLL, B-PLL expresses one or more B cell antigens (CD20, CD22, FMC7, CD79a) and lacks T cell antigens. (See
         <a class="medical medical_review" href="/z/d/html/4747.html" rel="external">
          "B cell prolymphocytic leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Mycosis fungoides/Sézary syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both T-PLL and mycosis fungoides (MF) are T cell neoplasms that can involve the blood and skin. The morphology of the "cerebriform" (Sézary cell-like) variant seen in 5 percent of patients with T-PLL resembles the Sézary cells that are prominent in Sézary syndrome and often seen in low numbers in MF. MF is diagnosed using an algorithm that incorporates clinical features, histology, immunophenotype, and molecular biology in a point-based system  (
         <a class="graphic graphic_table graphicRef74457" href="/z/d/graphic/74457.html" rel="external">
          table 2
         </a>
         ). A diagnosis of MF is made when a total of four points or more is determined. (See
         <a class="medical medical_review" href="/z/d/html/16193.html" rel="external">
          "Clinical presentation, pathologic features, and diagnosis of Sézary syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Chronic lymphocytic leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both T-PLL and chronic lymphocytic leukemia (CLL) can present with lymphocytosis and splenomegaly and have circulating prolymphocytes in the blood.
        </p>
        <p>
         Typical CLL cells are small, mature-appearing lymphocytes with a dense nucleus, partially aggregated chromatin, and without discernible nucleoli. There is a narrow border of pale or slightly basophilic cytoplasm  (
         <a class="graphic graphic_picture graphicRef54469" href="/z/d/graphic/54469.html" rel="external">
          picture 3
         </a>
         ). Prolymphocytes usually comprise fewer than 10 percent of the circulating cells. Most importantly, CLL is a B cell neoplasm and demonstrates both expression of B cell-associated antigens (CD19, CD20, and CD23) and the T cell-associated antigen CD5. T-PLL does not express B cell-associated antigens. (See
         <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">
          "Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Adult T cell leukemia-lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adult T cell leukemia-lymphoma (ATL) is a peripheral T cell neoplasm associated with infection by the human T-lymphotropic virus, type I (HTLV-I). Serologic and polymerase chain reaction (PCR) testing for HTLV-I is used to exclude this diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/4697.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Hairy cell leukemia and hairy cell leukemia variant
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cytoplasm of T-PLL can demonstrate cytoplasmic protrusions or blebs that may resemble the projections seen in the circulating tumor cells of hairy cell leukemia (HCL) and hairy cell leukemia variant (HCLv). Hairy cells strongly express pan-B cell antigens (CD19, CD20, CD22) and usually lack expression of CD5, CD10, CD21, and CD23. Hairy cells also characteristically express CD11c, CD25, CD103, CD123, cyclin D1, and annexin A1. HCLv is more likely to have a morphology that is reminiscent of T-PLL, including intermediate-sized cells with nucleoli and irregular nuclear contours, but is easily distinguished from T-PLL by immunophenotyping, which reveals expression of B cell markers (CD19, CD20, CD22) and the absence of T cell markers. (See
         <a class="medical medical_review" href="/z/d/html/4532.html" rel="external">
          "Clinical features and diagnosis of hairy cell leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          T cell large granular lymphocyte leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both T-PLL and T cell large granular lymphocyte (LGL) leukemia can present with a peripheral blood lymphocytosis, although in T-LGL this is rarely high. The tumor cells of LGL leukemia are characterized by their large size (15 to 18 microns), abundant cytoplasm containing typical azurophilic granules, a reniform or round nucleus, and a mature post-thymic immunophenotype. They express CD8 and CD57 with or without the expression of CD16 and the natural killer cell marker CD56  (
         <a class="graphic graphic_algorithm graphicRef80765" href="/z/d/graphic/80765.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4536.html" rel="external">
          "Treatment of large granular lymphocyte leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – T cell prolymphocytic leukemia (T-PLL) is a rare T cell neoplasm comprised of lymphoid cells, typically with involvement of the peripheral blood, bone marrow, and spleen. It is most common in older adults. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients typically present with an elevated white blood count (usually &gt;100,000/microL), often with few other symptoms. On examination, hepatosplenomegaly and generalized lymphadenopathy are common. Anemia, thrombocytopenia, skin infiltration, and serous effusions can be seen but are less common. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – Evaluation of suspected cases should include examination of the peripheral blood coupled with immunostains, flow cytometry, and cytogenetic studies. Evaluation of the bone marrow is not usually necessary but is included in the evaluation of patients with unexplained cytopenias or diagnostic uncertainty. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The peripheral blood will demonstrate &gt;5000/microL (5 x 10
         <sup>
          9
         </sup>
         /L) of cells with a T-PLL phenotype. Tumor cells express high levels of CD52 and also express pan-T cell markers (CD2, CD3, and CD7) and TCL1 or MTCP1. Abnormalities of 14q32 or Xq28 are characteristic. Serologic and polymerase chain reaction testing for human T-lymphotropic virus, type I, is negative. Criteria for diagnosis have been proposed by The T-PLL International Study Group (TPLL-ISG). (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of T-PLL includes other lymphoid neoplasms with a leukemic presentation  (
         <a class="graphic graphic_table graphicRef56540" href="/z/d/graphic/56540.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78:3269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herling M, Khoury JD, Washington LT, et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004; 104:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986; 63:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain P, Aoki E, Keating M, et al. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol 2017; 28:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991; 55:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staber PB, Herling M, Bellido M, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 2019; 134:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garand R, Goasguen J, Brizard A, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire. Br J Haematol 1998; 103:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magro CM, Morrison CD, Heerema N, et al. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol 2006; 55:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herling M, Valbuena JR, Jones D, Medeiros LJ. Skin involvement in T-cell prolymphocytic leukemia. J Am Acad Dermatol 2007; 57:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu Z, Medeiros LJ, Fang L, et al. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. Am J Hematol 2017; 92:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998; 103:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pekarsky Y, Hallas C, Isobe M, et al. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci U S A 1999; 96:2949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 1993; 8:2475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun Y, Tang G, Hu Z, et al. Comparison of karyotyping, TCL1 fluorescence in situ hybridisation and TCL1 immunohistochemistry in T cell prolymphocytic leukaemia. J Clin Pathol 2018; 71:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 2014; 124:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stilgenbauer S, Schaffner C, Litterst A, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997; 3:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vorechovský I, Luo L, Dyer MJ, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997; 17:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hetet G, Dastot H, Baens M, et al. Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia. Hematol J 2000; 1:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Babapulle V, Hamoudi R, Matutes E, et al. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome. Br J Haematol 2000; 110:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costa D, Queralt R, Aymerich M, et al. High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. Cancer Genet Cytogenet 2003; 147:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergmann AK, Schneppenheim S, Seifert M, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2014; 53:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López C, Bergmann AK, Paul U, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol 2016; 173:265.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4745 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1742486" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15044256" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3487341" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28379307" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1913594" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8555463" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Leukemia and lymphoma in ataxia telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31292114" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827924" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16342661" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16908353" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17707160" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Skin involvement in T-cell prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28194886" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9614908" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10077617" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8361760" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28821581" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Comparison of karyotyping, TCL1 fluorescence in situ hybridisation and TCL1 immunohistochemistry in T cell prolymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24825865" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9334731" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Biallelic mutations in the ATM gene in T-prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9288106" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11920168" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10930996" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14580769" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24446122" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26917488" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
